Who are Probiotic Vivomixx's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Probiotic : Saccharomyces boulardii, Bio-three, Probiotics(VSL#3), Ganeden BC30, INF108F probiotic, Lactobacillus plantarum.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/probiotic-vivomixx.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Probiotic Vivomixx — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Probiotic Vivomixx (Probiotic Vivomixx) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastroenterology.

marketed Probiotic Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Probiotic Vivomixx (Probiotic Vivomixx) — University of Milan. Vivomixx is a multi-strain probiotic formulation that restores beneficial gut microbiota to improve intestinal barrier function and modulate immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Probiotic Vivomixx TARGET	Probiotic Vivomixx	University of Milan	marketed	Probiotic
Probiotic : Saccharomyces boulardii	Probiotic : Saccharomyces boulardii	Biocodex	marketed	Probiotic
Bio-three	Bio-three	Kaohsiung Veterans General Hospital.	marketed	Probiotic
Probiotics(VSL#3)	Probiotics(VSL#3)	Govind Ballabh Pant Hospital	marketed	Probiotic
Ganeden BC30	Ganeden BC30	Massachusetts General Hospital	marketed	Probiotic
INF108F probiotic	INF108F probiotic	Massachusetts General Hospital	marketed	Live biotherapeutic product (probiotic)
Lactobacillus plantarum	Lactobacillus plantarum	Shenzhen People's Hospital	marketed	Probiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Probiotic Vivomixx — Competitive Intelligence Brief. https://druglandscape.com/ci/probiotic-vivomixx. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing